OncoSec Medical Inc (ONCSQ)

[Titan V]

Relevant but not directly related...

Molecular Med Tri-Con 2017
IMMUNOSEQUENCING AND CANCER MEDICINE
Profiling of Exhausted T Cells in Tumors Predicts PD-1 Response
Adil Daud, M.D., HS Clinical Professor, Medicine (Hematology/Oncology); Director, Melanoma Clinical Research, Helen Diller Comprehensive Cancer Center, University of California, San Francisco
Immune checkpoint blockade is revolutionizing therapy for advanced cancer. However, many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. We performed multi-parameter flow cytometry on freshly isolated metastatic melanoma samples prior to treatment and correlated subsequent clinical response with tumor immune phenotype.

http://www.triconference.com/Personalized-Diagnostics/